BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
UTHR upcoming catalysts
United Therapeutics: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 4 readout(s) and 0 FDA event(s). Subscribe to UTHR (.ics).
Drugs: Ralinepag
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | United Therapeutics UTHR | NCT03683186 A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseas | enrolling by invitation | 1000 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No FDA decision events in this window. | |||||
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-06-30 est. | P3 | United BioPharma UTHR | NCT04406727 UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection | HIV-1 Infection | unknown | 50 |
| 2026-02-02 | P3 | United Therapeutics UTHR | NCT04708782 Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease | completed | 598 |
| 2025-12-31 | P3 | United Therapeutics UTHR | NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseas | completed | 687 |
| 2025-12-31 est. | P3 | United BioPharma UTHR | NCT03149211 To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults | HIV-1 Infection | withdrawn |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.